Near-term growth catalysts:
• Major announcements and strategic partnerships to be completed for MXC’s Australian medical cannabis genetics and breeding research, clinical trials, and production strategy
• Plans to commence first Australian MC clinical trials in 2017 – with leading medical institutions
Sentiment - accumulate
Ann: Investor Presentation - March 2017, page-2
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.025(7.58%) |
Mkt cap ! $14.76M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 30.0¢ | $1.48K | 4.929K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 823 | 3 |
View Market Depth
| Last trade - 15.11pm 30/08/2024 (20 minute delay) ? |
| RGT (ASX) Chart |